GlassScriptPhysician profile
James H West
NPI 1891779344
$8,277.56
in general payments reported to CMS, 2019-2025
42 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $1,501 · 2021: $2,075 · 2022: $1,072 · 2023: $827 · 2024: $748 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Education: $99.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.71 |
| Education | $99.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $995.62 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $837.51 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $685.52 | 2019-2022 | |
| Allergan, INC. | $678.70 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $676.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $487.88 | 2019-2022 | |
| Pfizer INC. | $380.06 | 2019-2024 | |
| Lilly USA, LLC | $331.68 | 2020-2025 | Zepbound, Mounjaro, Kisunla |
| Sanofi-Aventis U.S. LLC | $315.43 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $306.05 | 2019-2024 | Livalo, Seglentis |
| Amgen INC. | $266.52 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $238.94 | 2023-2025 | Edarbi, Edarbyclor, Horizant |
| Amarin Pharma, INC. | $236.68 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.01 | 2019-2023 | Jardiance |
| Alkermes, INC. | $148.96 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.